4D Molecular 制药 FDMT
$12.25 +$1.00 (+8.89%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $12.25 0.00%
开盘$11.46
昨收$11.25
当日区间$11.28 – $12.57
成交量993.3K
市值$676.74M
市盈率（TTM）–
股息率–
FDMT 相关新闻
匹配 4D Molecular Therapeutics 或代码 FDMT 的头条新闻，按最新排序。
- Morgan Stanley Maintains 4D Molecular Therapeutics(FDMT.US) With Hold Rating
- BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $33
- Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)
- Cantor Fitzgerald Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating
- Cantor Fitzgerald Upgrades 4D Molecular Therapeutics(FDMT.US) to Buy Rating, Announces Target Price $20 正面
- A Quick Look at Today's Ratings for 4D Molecular Therapeutics(FDMT.US), With a Forecast Between $35 to $36
- Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)
- H.C. Wainwright Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $36
- Cantor Fitzgerald Maintains 4D Molecular Therapeutics(FDMT.US) With Hold Rating
- Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and 4D Molecular Therapeutics (FDMT)
- Analysts Have Conflicting Sentiments on These Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM)
- BofA Securities Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $29
- Evercore Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $23
- Chardan Capital Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Maintains Target Price $26
- Goldman Sachs Maintains 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Cuts Target Price to $33 负面
暂无评论——快来第一个聊聊 FDMT。
登录后参与讨论。